|
|
|
|
|
Teisinis statusas
Patentas neįsigaliojo (pagal EPK)
| (51) | INT.CL. | C07K 14/725 | (2006.01) |
| C07K 14/7051 | (2013.01) | ||
| A61K 31/505 | (2006.01) | ||
| A61K 31/7088 | (2013.01) | ||
| A61K 45/06 | (2013.01) | ||
| A61K 38/00 | (2013.01) | ||
| A61K 35/17 | (2013.01) | ||
| C12N 5/0636 | (2013.01) | ||
| C12N2510/00 | (2013.01) | ||
| A61P 35/02 | (2018.01) | ||
| A61K2039/5156 | (2013.01) | ||
| A61K2039/5158 | (2013.01) | ||
| A61K 39/001112 | (2018.08) |
| (11) | Patento numeris | 3959235 |
| (13) | Dokumento rūšis | T |
| (96) | Europos patento paraiškos numeris | 20728258.3 |
| Europos patento paraiškos padavimo data | 2020-04-24 | |
| (97) | Europos patento paraiškos paskelbimo data | 2022-03-02 |
| (45) | Paskelbimo apie Europos patento išdavimą data | 2023-07-26 |
| (46) | Apibrėžties vertimo paskelbimo data |
| (86) | Numeris | PCT/US2020/029775 |
| Data | 2020-04-24 |
| (87) | Numeris | WO 2020/219848 |
| Data | 2020-10-29 |
| (30) | Numeris | Data | Šalis |
| 201962839455 P | 2019-04-26 | US | |
| 202063005041 P | 2020-04-03 | US |
| (72) |
PERTEL, Thomas Charles , US
SASU, Barbra Johnson , US
LEONARD, Mark W. , US
|
| (73) |
Allogene Therapeutics, Inc. ,
210 E. Grand Avenue, South San Francisco, CA 94080,
US
|
| (54) | RITUXIMAB-RESISTANT CHIMERIC ANTIGEN RECEPTORS AND USES THEREOF |
| RITUXIMAB-RESISTANT CHIMERIC ANTIGEN RECEPTORS AND USES THEREOF |